Conavi Medical announces public offering of shares and warrants

Conavi Medical Corp. (TSXV: CNVI) filed a preliminary prospectus for a public offering of common shares and pre-funded warrants with securities regulators in British Columbia, Alberta and Ontario.

The medical device company will conduct the offering through Bloom Burton Securities Inc. on a commercially reasonable efforts agency basis. The number of securities, offering size and pricing will be determined through negotiations between Conavi Medical and the agent based on market conditions.

Conavi Medical plans to use proceeds to obtain U.S. FDA 510(k) clearance for its next-generation Novasight Hybrid system and conduct a limited market release followed by a broader commercial launch in the United States. Additional funds will support working capital and general corporate purposes.

The offering is expected to close around December 12, 2025, subject to a definitive agency agreement and customary closing conditions, including regulatory and TSX Venture Exchange approvals. The securities may also be offered through private placements in certain jurisdictions outside Canada.

The Toronto-based company develops imaging technologies for minimally invasive cardiovascular procedures. Its Novasight Hybrid system combines intravascular ultrasound and optical coherence tomography in a single device for coronary artery imaging. The first-generation system has regulatory clearance in the United States, Canada, China and Japan.

The preliminary prospectus is available on SEDAR+ at www.sedarplus.ca. The securities have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• K Wave Media prices $1M registered direct offering at $1.90 per share
• Nebius Group prices upsized $5B convertible notes offering